http://wee1pathway.com/index.p....hp/the-at-any-time-c
As autologous stem-cell transplantation (SCT) continues to be the standard of care for second-line therapy of many patients with rr-cHL, optimization of second-line regimens by using brentuximab vedotin, or, as time goes on, checkpoint inhibitors, is promising to boost both the qualifications rate for transplant and also the last outcome. The need for subsequent treatment, and particularly allogeneic SCT, can be paid off with brent
Like
Comment
Share
